# Cirius Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cirius-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Kalamazoo, US
- Website: www.ciriustx.com
- Total disclosed funding: $49M
- Latest round: Series A (Aug 23, 2018)
- Investors on record: 5

## About

Cirius Therapeutics, Inc. is a biotechnology company focused on developing innovative therapies to address diseases related to insulin resistance, particularly Type 2 Diabetes and Obesity.Cirius Therapeutics, Inc. was founded in 2015 and is headquartered in Kalamazoo, US. The company specializes in creating therapies for chronic metabolic diseases. In May 2019, Cirius raised USD 7.5 million in Series A funding, which is the total amount raised to date, and is actively involved in four deals since inception. The current company valuation stands at USD 117.236 mn.Cirius Therapeutics develops innovative therapies focused on addressing diseases associated with insulin resistance, specifically targeting Type 2 Diabetes and Obesity. Their core product, 0602K, is designed to improve metabolic function and reduce insulin resistance, with ongoing research into its efficacy both as a standalone treatment and in combination with Tirzepatide. Cirius primarily serves markets in North America and Europe, aiming to enhance health outcomes for patients suffering from these chronic conditions.Cirius Therapeutics generates revenue through collaborative partnerships and clinical trial agreements with pharmaceutical companies and healthcare organizations. The business model is structured around B2B transactions, where agreements typically involve milestone payments connected to the progress of clinical trials and successful product development phases. The flagship product, 0602K, is central to these partnerships as it represents a pivotal element in the company’s therapeutic portfolio.Cirius Therapeutics plans to utilize the recent funding of USD 7.5 million raised in May 2019 to support the continued research and development of new products, including potential next-generation therapies targeting insulin resistance. The company is also exploring expansion opportunities into international markets by 2022, particularly in Europe and Asia, where the need for advanced therapeutic options for Type 2 Diabetes and Obesity is growing.

## Funding rounds

- Series A, Aug 23, 2018, $9M — Adams Street Partners, Frazier Healthcare Partners, Novo Holdings
- Series A, Apr 11, 2017, $40M — Adams Street Partners, Frazier Healthcare Partners, Renaissance Venture Capital, Hopen Life Science Ventures, Novo Holdings

## Investors

- Adams Street Partners (https://capitalatlas.ai/funds/adams-street-partners) — Series A
- Frazier Healthcare Partners (https://capitalatlas.ai/funds/frazier-healthcare-partners) — Series A
- Renaissance Venture Capital (https://capitalatlas.ai/funds/renaissance-venture-capital) — Series A
- Hopen Life Science Ventures (https://capitalatlas.ai/funds/hopen-life-science-ventures) — Series A
- Novo Holdings — Series A